Brief: Celularity - On April 29 Received E-Mail Notification From FDA Regarding Cycart-19 Ind - Filing

Celularity

03/05/2022 22:26

May 3 (Reuters) - Celularity Inc  CELU.O :
    * CELULARITY - ON APRIL 29 RECEIVED E-MAIL NOTIFICATION FROM
FDA
REGARDING CYCART-19 IND - FILING
    * CELULARITY - FDA SAYS IT WILL BE SEEKING ADDITIONAL
INFORMATION
BEFORE CO CAN PROCEED WITH PLANNED PHASE 1/2 CLINICAL TRIAL FOR
CYCART-19
    * CELULARITY - EXPECTS TO RECEIVE FORMAL WRITTEN
COMMUNICATION
WITH ADDITIONAL INFORMATION FROM THE FDA BY LATE MAY
    * CELULARITY - PLANS TO WORK WITH THE FDA IN AN EFFORT TO
RESOLVE
ITS QUESTIONS AS PROMPTLY AS POSSIBLE FOR CYCART-19
    * CELULARITY - EXPECTS TO COMMENCE TRIAL IN SECOND HALF OF
2022,
ASSUMING CLEARANCE OF CYCART-19 IND

Source text: [ID: https://bit.ly/3kCAUao]
Further company coverage:  CELU.O 

 ((Reuters.Briefs@thomsonreuters.com;))